RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform
Collaboration will explore trans-arterial delivery of Imugene's CF33 oncolytic virus utilizing RenovoRx's TAMP therapy platformTAMP enables localized, targeted delivery of CF33 to difficult-to-access tumors, such as pancreatic and liver
Source: prwire.com.au
